TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03458442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based surgical training
Description: Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical training
Description: Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard surgical training
Description: Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
Study: NCT03426592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3, 10000 Intl Units Oral Capsule
Description: Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.
Study: NCT01376999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-r (Follicule stimulate hormone)
Description: Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH-r (Follicule stimulate hormone)
Description: Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
Study: NCT03139851

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide 50mg
Description: One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab 100 MG in 4 ML Injection
Description: IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT03428152

Intervention type: PROCEDURE
Intervention: superior hypogastric block
Description: superior hypogastric blockade during surgery
Study: NCT00108355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Saline Infusion (Albumin placebo)
Description: Intravenous saline Infusion (Albumin placebo)
Study: NCT00523848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Oral
Study: NCT03832764

Intervention type: DEVICE
Intervention: ANSPEC-PRO
Description: Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU

Intervention type: DEVICE
Intervention: ANSPEC-PRO
Description: Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
Study: NCT05261542

Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry
Description: evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium

Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry
Description: evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium
Study: NCT01155856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital
Description: For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
Study: NCT04752956

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total nasal symptom score (TNSS)
Description: TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total nasal symptom score (TNSS)
Description: TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total nasal symptom score (TNSS)
Description: TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.
Study: NCT00108355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine oral tablet at 10 mg three times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tablet (Midodrine placebo)
Description: Oral tablet (Midodrine placebo) three times a day
Study: NCT01945814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL for CMV seropositive donors
Description: CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL for CMV naïve donors
Description: CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
Study: NCT03485963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HST-NEETs
Description: The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
Study: NCT00580151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 3-5 microgram per kilogram every 6 hours for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 dose every 6 hours
Study: NCT03514459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach
Description: SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement \[CQI\] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
Study: NCT01757093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation plus CPAP
Description: SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Tube Compensation plus CPAP
Description: SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: SPONTANEOUS BREATHING TRIAL WITH CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: SPONTANEOUS BREATHING TRIAL WITH CPAP
Study: NCT04425057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training
Study: NCT00929370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine Transporter-1 inhibitor
Description: GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
Study: NCT02789774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior fusion C1-C2
Description: Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid cervical collar
Description: External immobilization of cervical spine in a rigid collar for 12 weeks.
Study: NCT00639756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo given for 2 weeks
Study: NCT02382575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
Study: NCT02573051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide mononitrate
Description: 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT01129427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pharmaceutical form: delayed-release tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pharmaceutical form: delayed-release tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: Pharmaceutical form: delayed-release tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: Pharmaceutical form: delayed-release tablet~Route of administration: oral
Study: NCT03689829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo s.c. injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo s.c. injections.
Study: NCT01365819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
Study: NCT03306745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Profertil female
Description: For micronutrient ingredients please see details above. PROfertil ® female is approved in Austria by the Austrian Ministry of Health and has a Free Sales Certificate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid 400 mg
Description: Folic acid 400 mg
Study: NCT04078594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sepsis e-alert
Description: At 2-each month interval, the e-alert will be activated in five new randomly selected wards, until all wards eventually will have active alert
Study: NCT04747158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2
Study: NCT01164020

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: 20g/d for 7 days followed by 5g/d for 23 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: 20g/d for 7 days followed by 5g/d for 23 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Dextrose)
Description: 20g/d for 7 days followed by 5g/d for 23 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Dextrose)
Description: 20g/d for 7 days followed by 5g/d for 23 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: resistance training twice a week for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: resistance training twice a week for 24 weeks
Study: NCT01226082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Patients will recieve tDCS in a 5-day period of treatment
Study: NCT02741076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Description: Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)